07-11-2006: Eurofins has recently become one of the major shareholders in Fasmac Co. Ltd. located in Kanagawa, Japan. This allows the Group to enter into the Japanese Genomics markets.
Fasmac (an abbreviation for Food Assessment and Management Center), a subsidiary of Nippon Flour Mills Co., is the leading GMO testing laboratory in Japan as well as a producer of high purity oligonucleotides. All the oligonucleotides for the Japanese standard GMO testing methods are provided from Fasmac in its role as operator of the patent for the Japanese Standard Method. Nippon Flour Mills, listed at the Tokyo stock exchange, is the second largest Japanese industrial flour miller and producer of flour-related products for industrial, food service, and domestic uses.
Fasmac is the exclusive licensee of Eurofins | GeneScan in Japan. Eurofins is Fasmac's exclusive licencee in the USA. Fasmac will be able to use the proven analytical procedures developed by Eurofins | GeneScan and intends to deliver the full range of Eurofins| GeneScan's PCR products and services directly to the Japanese market.
It is planned that Eurofins will increase its stake in Fasmac over time. Initially, Fasmac will not be fully consolidated in the Eurofins Scientific accounts due to the percentage of Eurofins' shareholding.
Eurofins Scientific has signed an agreement to acquire a 52.6% majority stake in Nihon Kankyo K.K. (Nihon Environmental Services, on 31 March 2012. The transaction is expected to be completed this week.Nihon Kankyo K.K. was founded almost 40 years ago and is based in the greater Tokyo area. ... more
Eurofins Scientific announces the successful closing of the transaction for a 67% majority stake in each of the two subsidiaries of the Fondation Institut Pasteur de Lille (IPL), namely IPL Invest and IPL Santé Environnement Durable Nord (IPL SED Nord), on the 31st of October, 2011.
As prev ... more
Following the signing of an exclusive discussion agreement with the Fondation Institut Pasteur de Lille (IPL), Eurofins Scientific announced that it has signed a definitive, mutually-binding agreement on to acquire a 67% stake in each of its two subsidiaries, namely IPL Invest and IPL Santé ... more